Treatment of Superficial Infantile Haemangiomas with Timolol and Propranolol
- Conditions
- Health Condition 1: D180- Hemangioma
- Registration Number
- CTRI/2021/05/033307
- Lead Sponsor
- Varun Gupta
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1.Children diagnosed with problematic infantile haemangioma, defined
a)Potentially disfiguring infantile haemangioma at any site.
b)Functionally threatening infantile haemangioma near the eyes, nose, natural orifices, limbs & genitalia.
c)Segmental infantile haemangioma.
d)Uncomplicated progressive infantile haemangioma.
2.Either sex.
3.Multiple haemangiomas.
Exclusion criteria
1.Infants with heart disease, cardiac arrhythmias.
2.Broncho-obstructive disease.
3.Premature infants with corrected age less than 40 weeks.
4.Known hypoglycaemia.
5.Hypertension.
6.Hypotension.
7.Pediatric patients who have deranged LFT.
8.Visceral haemangiomas.
9.PHACES syndrome (Posterior fossa brain malformations, Hemangioma, Arterial lesions, Cardiac abnormalities, and Eye abnormalities).
10.Ulcerative haemangiomas.
11.Previously treated patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the size of superficial Infantile haemangioma <br/ ><br> <br/ ><br>Timepoint: 0 week, 4wks, 8wks, 12wks, 16wks, 20wks, 24wks, 28wks, 32wks.
- Secondary Outcome Measures
Name Time Method To assess the adverse event seen with the study drugs. <br/ ><br>To assess the increase or decrease of size of haemangiomaTimepoint: 0 week, 4wks, 8wks, 12wks, 16wks, 20wks, 24wks, 28wks, 32wks.